Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

SHE:002262 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,783	1,416	2,159	1,532	1,608	1,402
Trading Asset Securities	2,183	2,373	1,335	1,452	1,058	837
Cash & Short-Term Investments	3,966	3,789	3,494	2,984	2,666	2,239
Cash Growth	3.13%	8.46%	17.08%	11.94%	19.05%	13.06%
Accounts Receivable	1,648	1,496	1,054	843.93	720.49	609.22
Other Receivables	76.68	49.07	41.84	42.52	27.61	19.35
Receivables	1,724	1,545	1,095	886.45	748.09	628.57
Inventory	880.81	661.39	628.64	716.34	604.33	433.86
Prepaid Expenses	-	5.45	0	0	4.81	-
Other Current Assets	77.51	57.84	36.63	63.4	19.96	17.73
Total Current Assets	6,649	6,060	5,255	4,650	4,043	3,320
Property, Plant & Equipment	1,571	1,609	1,496	1,304	1,158	1,034
Long-Term Investments	155.44	125.31	106.77	118.61	130.41	81.23
Other Intangible Assets	227.48	232.09	190.47	111.1	95.98	101.04
Long-Term Deferred Tax Assets	43.03	55.39	58.32	36.95	30.66	31.2
Long-Term Deferred Charges	314.75	263.61	128.03	131.88	80.51	25.95
Other Long-Term Assets	119.29	95.2	94.05	128.51	158.09	155.18
Total Assets	9,080	8,440	7,328	6,481	5,697	4,748
Accounts Payable	494.55	568.35	277.2	255.74	267.17	165.19
Accrued Expenses	-	180.54	296.13	297.36	53.09	38.73
Short-Term Debt	-	15	55	30	38	38
Current Portion of Leases	20.82	20.18	20.86	20.63	25.01	-
Current Income Taxes Payable	181.36	91.28	84.1	83.5	80.85	97.91
Current Unearned Revenue	28.07	41.53	26.49	26.7	24.11	41.07
Other Current Liabilities	187.39	149.37	54.26	80.02	193.72	194.05
Total Current Liabilities	912.19	1,066	814.03	793.94	681.96	574.95
Long-Term Debt	0.23	0.23	0.23	0.23	0.23	0.23
Long-Term Leases	25.68	33.87	35.56	41.91	47.67	-
Long-Term Unearned Revenue	41.41	41.41	53.87	58.05	63.6	67.77
Long-Term Deferred Tax Liabilities	-	0.11	1.46	3.3	-	-
Other Long-Term Liabilities	24.64	24.64	12.95	-	-	-
Total Liabilities	1,004	1,166	918.09	897.43	793.45	642.94
Common Stock	1,016	1,016	1,008	1,008	1,008	1,008
Additional Paid-In Capital	277.35	244.18	102.99	119.41	119.41	49.85
Retained Earnings	6,878	6,138	5,317	4,481	3,783	3,086
Treasury Stock	-68.3	-98.86	-	-	-	-35.32
Comprehensive Income & Other	0.87	0.87	6.75	13.1	10.95	15.09
Total Common Equity	8,104	7,300	6,434	5,622	4,921	4,123
Minority Interest	-28.33	-26.81	-24.03	-37.79	-16.96	-17.5
Shareholders' Equity	8,076	7,274	6,410	5,584	4,904	4,105
Total Liabilities & Equity	9,080	8,440	7,328	6,481	5,697	4,748
Total Debt	46.72	69.27	111.64	92.77	110.91	38.23
Net Cash (Debt)	3,920	3,720	3,382	2,891	2,555	2,201
Net Cash Growth	5.03%	9.99%	16.98%	13.16%	16.08%	13.31%
Net Cash Per Share	3.86	3.68	3.36	2.86	2.53	2.17
Filing Date Shares Outstanding	1,016	1,016	1,008	1,008	1,008	1,008
Total Common Shares Outstanding	1,016	1,016	1,008	1,008	1,008	1,008
Working Capital	5,737	4,993	4,441	3,856	3,361	2,745
Book Value Per Share	7.98	7.18	6.39	5.58	4.88	4.09
Tangible Book Value	7,876	7,068	6,244	5,510	4,825	4,022
Tangible Book Value Per Share	7.75	6.96	6.20	5.47	4.79	3.99
Buildings	-	613.6	599.08	593.38	569.55	604.46
Machinery	-	1,546	1,341	1,251	1,088	934.72
Construction In Progress	-	309.38	293.76	92.07	17.21	3.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.